Shanghai. August 2. INTERFAX-CHINA - Beijing Huashen Pharmaceutical Ltd., a subsidiary of the China Academy of Chinese Medicine Sciences, has launched a medicine to treat lung cancer.
The medicine, Yi Fei Qing Hua granule, was developed by a chief researcher in the academy, who started to cancer study treatment in 1970s.
The unnamed researcher received government awards for his study on the treatment of late stage primary lung cancer patients with Yi Fei Qing Hua capsules.
"The granule is a compound medicine, and has adequate efficacy and low cost," Zhu Xichun, a manager at Beijing Huashen told Interfax. "The medicine is more effective than chemotherapy in controlling cancer by increasing immunization function, and extending life expectancy."
The medicine was made from Radix Astragali, Codonopsis pilosula, almond, and Platycodon grandiflorum, was prepared in the form of oral solution, branded Fei Liu Ping Gao, and used in Guang'anmen Hospital of China Academy of Medical Sciences.
A contrast clinical study of the medicine was made in the 1990s, and involved 195 cases of primary lung cancer patients at a late stage, treated with Fei Liu Ping Gao, and 144 cases, with chemotherapy.
The result showed that coughs, phlegm, chest pain, shortness of breath and fatigue of the patients in the treatment group improved markedly compared with the chemotherapy group.
By short term efficacy, the X-ray showed that of the 195 cases treated with Fei Liu Ping Gao, 2 were improved, 166 remained stable, and 27 deteriorated. In the 144 cases of the chemotherapy group, 10 were improved, 70 remained stable and 64 deteriorated.
The observation of long term efficacy on the patients showed that of the 28 patients treated with Fei Liu Ping Gao, 6 survived for one year after the treatment, 15 for two years, 4 within three years, and 3 survived for more than three years.
In the 14 cases of the chemotherapy group, 14 survived for one year, and the rest survived for two years. The average survival periods for patients in the treatment group were 12.5 months, and the chemotherapy group, 7.5 months.
Beijing Huashen Pharmaceutical Ltd. introduced TCM production facilities and used an advanced spray-drying granule production method, to prepare Fei Liu Ping Gao oral solution into the Yi Fei Qing Hua granule. The spry-drying method can retain the properties of natural medicines, and enable drugs to be taken at low dosage.
It can also strengthen the efficacy of chemotherapy when used concurrently with other drugs, and has low gastrointestinal and liver toxicity effects.
"Patients need to pay RMB 1000 (USD 125) per month for the treatment, which is cheap compared with other chemotherapy," Zhu said.
Beijing Huashen Pharmaceutical Ltd. is a joint venture of the China Academy of Medical Sciences and Hong Kong-listed China Resources Holdings Ltd.